Craig-Hallum raised the firm’s price target on Koru Medical (KRMD) to $6 from $5 and keeps a Buy rating on the shares. Koru Medical’s Q4 pre-release points to another “nice” quarter for the company, and a cash flow positive one, the analyst tells investors in a research note. The firm is focused on continued commercial execution and international expansion to drive above market growth in 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD: